The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2103-2110

  Ruan, Min ^a   Thorn, Katherine ^b   Liu, Shengwen ^a   Li, Siyi ^a   Yang, Wenjun ^a   Zhang, Chunye ^a   Zhang, Chenping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Activator protein 1; IL 6; Immune response; Oral squamous cell carcinoma; Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; CURCUMIN; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER IMMUNOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUTH TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR CELL LINE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MOUTH NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP-1;

EID: 84899500805     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2356     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Ferlay J, Shin HR, Bray F, Forman D and Mathers C: GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed July 20, 2012.
3. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003.
4. Melief CJ: Cancer: immune pact with the enemy. Nature 450: 803-804, 2007.
5. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
6. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
7. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004.
8. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, et al: IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19: 725-737, 2003.
9. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S and Medzhitov R: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241, 2004.
10. El-Omar EM, Ng MT and Hold GL: Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27: 244-252, 2008.
11. O'Neill LA: Signal transduction pathways activated by the IL-1 receptor/Toll-like receptor super family. Curr Top Microbiol Immunol 270: 47-61, 2002.
12. Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol 17: 1-14, 2005.
13. Ruan M, Zun Z, Siyi L, Wenjun Y, Lizheng W, et al: Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Arch Oral Biol 56: 877-884, 2011.
14. Min R, Siyi L, Wenjun Y, Shengwen L, Ow A, et al: Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells. Cancer Sci 103: 1938-1945, 2012.
15. Sdek P, Zhang ZY, Cao J, Pan HY, Chen WT, et al: Alteration of cell-cycle regulatory proteins in human oral epithelial cells immortalized by HPV16 E6 and E7. Int J Oral Maxillofac Surg 35: 653-657, 2006.
16. Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L, et al : Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 53: 443-452, 2008.
17. Ruan M, Ji T, Yang WJ, Duan WH, Zhou XJ, et al: Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-κB pathway. Phytother Res 22: 407-415, 2008.
18. Kaomongkolgit R, Cheepsunthorn P, Pavasant P and Sanchavanakit N: Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 44: 587-594, 2008.
19. Toualbi-Abed K, Daniel F, Güller MC, Legrand A, Mauriz JL, et al: Jun D cooperates with p65 to activate the proximal κB site of the cyclin D1 promoter: role of PI3K/PDK-1. Carcinogenesis 29: 536-543, 2008.
20. Woods KV, El-Naggar A, Clayman GL and Grimm EA: Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58: 3132-3141, 1998.
21. St John MA, Li Y, Zhou X, Denny P, Ho CM, et al: Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130: 929-935, 2004.
22. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, et al : Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 106: 683-689, 2003.
23. Okamoto M, Hiura K, Ohe G, Ohba Y, Terai K, et al: Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 89: 1966-1975, 2000.
24. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, et al: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5: 42, 2005.
25. Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146, 1997.
26. Smith HA and Kang Y: The metastasis-promoting roles of tumor-associated immune cells. J Mol Med 91: 411-429, 2013.
27. Beetz A, Peter RU, Oppel T, Kaffenberger W, Rupec RA, et al: NF-kappaB and AP-1 are responsible for inducibility of the IL-6 promoter by ionizing radiation in HeLa cells. Int J Radiat Biol 76: 1443-1453, 2000.
28. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, et al: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315-325, 1997.
29. Mishra A, Bharti AC, Saluja D and Das BC: Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer 126: 819-829, 2010.
30. Rao SK, Pavicevic Z, Du Z, Kim JG, Fan M, Jiao Y, et al: Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 285: 32512-32521, 2010.
31. Lin CM, Chen YH, Ma HP, Wang BW, Chiu JH, et al: Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agric Food Chem 60: 12451-12457, 2012.
32. Houghton AN, Uchi H and Wolchok JD: The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 7: 403-405, 2005.
33. Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H: TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224, 2008.
34. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330, 2008.
35. Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, et al: Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 29: 2667-2674, 2011.